DeepLife
DeepLife is a biotechnology company that develops digital twins of cells for drug discovery( The company uses state-of-the-art multi-omics data( artificial intelligence( and systems engineering to identify molecular triggers that drive diseased cells back to their healthy state( The platform offers OmicStore for multi-omics data management( Cell Blueprint for cellular modeling( and a TechDemo for demonstration…
Funding snapshot
About
DeepLife is a biotechnology company that develops digital twins of cells for drug discovery( The company uses state-of-the-art multi-omics data( artificial intelligence( and systems engineering to identify molecular triggers that drive diseased cells back to their healthy state( The platform offers OmicStore for multi-omics data management( Cell Blueprint for cellular modeling( and a TechDemo for demonstration purposes( DeepLife's approach enables researchers to map life one cell at a time( creating computational models that simulate cellular behavior for drug target identification and therapeutic intervention( The company's tools use machine learning technology to process biological data( perform genomic screening( and provide insights into target proteins for individual patient treatments( Founded in 2019 and headquartered in Paris( France( the company has raised $16.4M in Series A funding from investors including YZR Capital( Beiersdorf( Groupe Prunay( Turenne Groupe( Paris Business Angels( Mid Atlantic Bio Angels( Entrepreneur First( Kima Ventures( Super Capital( and Nord Capital Partenaires.
Business model
Life Sciences Tech > Research & Development > Drug Informatics > Clinical Data Analysis > Omics Analysis,
Genomics > Genome Informatics > Integrative Bioinformatics Platforms
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.